Pharmaceutical - Markets & Marketing, UCB


Current filters:

Markets & MarketingUCB

Popular Filters

Global epilepsy market to reach $4.5 billion by 2019

Global epilepsy market to reach $4.5 billion by 2019


The epilepsy therapeutics market value in the eight major countries - the USA, Canada, France, Germany,…

EisaiFycompaGlaxoSmithKlineGlobalMarkets & MarketingNeurologicalPharmaceuticalTrobaltUCBVimpat

Asia-Pacific epilepsy therapeutics market continues to grow as new drugs emerge


The epilepsy therapeutics market value in the Asia-Pacific region - Australia, China, India and Japan…

Asia-PacificEisaiFycompaGlaxoSmithKlineKeppraMarkets & MarketingNeurologicalPharmaceuticalTrobaltUCBVimpatZonegran

Lupus therapeutics boast blockbuster hopefuls as R&D continues, says GlobalData


Lupus therapeutics are lacking, and patients with moderate forms of the disease are greatly underserved,…

BenlystaBiotechnologyBristol-Myers SquibbepratuzumabGlaxoSmithKlineImmunologicalsMarkets & MarketingOrenciaPharmaceuticalRare diseasesResearchUCB

AbbVie/Eisai's Humira has best clinical profile among psoriatic arthritis treatments


Based on clinical data and the opinions of interviewed thought leaders interviewed by health care advisory…

AbbVieAnti-Arthritics/RheumaticsAstellas PharmaBiotechnologyCimziaEisaiEuropeHumiraMarkets & MarketingNorth AmericaPharmaceuticalUCB

Switch to anabolics driving osteoporosis market growth


A major paradigm shift in late and mid-stage product development from anti-resorptive therapies to anabolic…

AmgenAnti-Arthritics/RheumaticsMarkets & MarketingPharmaceuticalromosozumabUCB

US gastroenterologists increasingly using biologics to treat Crohn's patients in remission


Although there have been no significant changes with regard to biologic treatment and Crohn's disease…

AbbVieBiotechnologyCimziaGastro-intestinalsHumiraJanssenMarkets & MarketingNorth AmericaPharmaceuticalRemicadeUCB

Leading dopamine agonists will continue to dominate Parkinson's market


The leading dopamine agonists, pramipexole (Boehringer Ingelheim's Mirapex/Mirapexin/Sifrol/BI-Sifrol,…

Boehringer IngelheimGlaxoSmithKlineGlobalMarkets & MarketingMirapexNeuproNeurologicalPharmaceuticalRequipRytaryUCB

UCB's Neupro re-launched in USA for Parkinson's and RSL


Belgium drugmaker UCB (Euronext Brussels: UCB) said yesterday that its Neupro (rotigotine transdermal…

Markets & MarketingNeuproNeurologicalNorth AmericaPharmaceuticalUCB

Opportunities for Pharma in narcolepsy


The narcolepsy therapeutics developmental pipeline is weak, with only six molecules in development, providing…

BioprojectCephalonGenericsMarkets & MarketingNeurologicalNuvigilPharmaceuticalProvigilResearchTeva Pharmaceutical IndustriesUCBXyrem

Back to top